Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat, Toripalimab, and Bevacizumab in advanced ESCC, AEG, and GC
NCT05163483Phase 2Recruiting
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in Esophageal Squamous Cell Carcinoma (ESCC), adenocarcinoma of the esophagogastric junction (AEG), gastric adenocarcinoma. Started Jul 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)adenocarcinoma of the esophagogastric junction (AEG)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05163483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163483.